234 related articles for article (PubMed ID: 10894285)
1. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples.
Hertogs K; Bloor S; Kemp SD; Van den Eynde C; Alcorn TM; Pauwels R; Van Houtte M; Staszewski S; Miller V; Larder BA
AIDS; 2000 Jun; 14(9):1203-10. PubMed ID: 10894285
[TBL] [Abstract][Full Text] [Related]
2. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies.
Race E; Dam E; Obry V; Paulous S; Clavel F
AIDS; 1999 Oct; 13(15):2061-8. PubMed ID: 10546858
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene.
Dronda F; Casado JL; Moreno S; Hertogs K; García-Arata I; Antela A; Pérez-Elías MJ; Ruiz L; Larder B;
AIDS Res Hum Retroviruses; 2001 Feb; 17(3):211-5. PubMed ID: 11177403
[TBL] [Abstract][Full Text] [Related]
4. Resistance testing in children changing human immunodeficiency virus type 1 protease inhibitor.
Servais J; Hainaut M; Schmitz V; Maes P; Fransen K; Vaira D; Brichard B; Arendt V; Schneider F; Hemmer R; Schmit JC
Pediatr Infect Dis J; 2002 Mar; 21(3):214-20. PubMed ID: 12005085
[TBL] [Abstract][Full Text] [Related]
5. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538).
Schmit JC; Ruiz L; Clotet B; Raventos A; Tor J; Leonard J; Desmyter J; De Clercq E; Vandamme AM
AIDS; 1996 Aug; 10(9):995-9. PubMed ID: 8853733
[TBL] [Abstract][Full Text] [Related]
6. Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.
Gonzalez LM; Santos AF; Abecasis AB; Van Laethem K; Soares EA; Deforche K; Tanuri A; Camacho R; Vandamme AM; Soares MA
J Antimicrob Chemother; 2008 Jun; 61(6):1201-4. PubMed ID: 18356151
[TBL] [Abstract][Full Text] [Related]
7. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
Schapiro JM; Winters MA; Lawrence J; Merigan TC
AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
[TBL] [Abstract][Full Text] [Related]
8. Quantitative evaluation of the recombinant HIV-1 phenotype to protease inhibitors by a single-step strategy.
Menzo S; Rusconi S; Monachetti A; Colombo MC; Violin M; Bagnarelli P; Varaldo PE; Moroni M; Galli M; Balotta C; Clementi M
AIDS; 2000 Jun; 14(9):1101-10. PubMed ID: 10894273
[TBL] [Abstract][Full Text] [Related]
9. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
Nijhuis M; van Maarseveen NM; Lastere S; Schipper P; Coakley E; Glass B; Rovenska M; de Jong D; Chappey C; Goedegebuure IW; Heilek-Snyder G; Dulude D; Cammack N; Brakier-Gingras L; Konvalinka J; Parkin N; Kräusslich HG; Brun-Vezinet F; Boucher CA
PLoS Med; 2007 Jan; 4(1):e36. PubMed ID: 17227139
[TBL] [Abstract][Full Text] [Related]
10. Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.
Giandhari J; Basson AE; Sutherland K; Parry CM; Cane PA; Coovadia A; Kuhn L; Hunt G; Morris L
Antimicrob Agents Chemother; 2016 Apr; 60(4):2248-56. PubMed ID: 26833162
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
[TBL] [Abstract][Full Text] [Related]
12. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
[TBL] [Abstract][Full Text] [Related]
13. Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance.
Schmidt B; Walter H; Moschik B; Paatz C; van Vaerenbergh K; Vandamme AM; Schmitt M; Harrer T; Uberla K; Korn K
AIDS; 2000 Aug; 14(12):1731-8. PubMed ID: 10985309
[TBL] [Abstract][Full Text] [Related]
14. Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors.
Kemper CA; Witt MD; Keiser PH; Dubé MP; Forthal DN; Leibowitz M; Smith DS; Rigby A; Hellmann NS; Lie YS; Leedom J; Richman D; McCutchan JA; Haubrich R;
AIDS; 2001 Mar; 15(5):609-15. PubMed ID: 11316998
[TBL] [Abstract][Full Text] [Related]
15. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
Santos AF; Abecasis AB; Vandamme AM; Camacho RJ; Soares MA
J Antimicrob Chemother; 2009 Mar; 63(3):593-9. PubMed ID: 19136678
[TBL] [Abstract][Full Text] [Related]
16. Prediction of drug-resistance in HIV-1 subtype C based on protease sequences from ART naive and first-line treatment failures in North India using genotypic and docking analysis.
Toor JS; Sharma A; Kumar R; Gupta P; Garg P; Arora SK
Antiviral Res; 2011 Nov; 92(2):213-8. PubMed ID: 21875619
[TBL] [Abstract][Full Text] [Related]
17. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors.
Colonno RJ; Thiry A; Limoli K; Parkin N
Antimicrob Agents Chemother; 2003 Apr; 47(4):1324-33. PubMed ID: 12654666
[TBL] [Abstract][Full Text] [Related]
18. A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes.
Doherty KM; Nakka P; King BM; Rhee SY; Holmes SP; Shafer RW; Radhakrishnan ML
BMC Bioinformatics; 2011 Dec; 12():477. PubMed ID: 22172090
[TBL] [Abstract][Full Text] [Related]
19. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug.
Mammano F; Trouplin V; Zennou V; Clavel F
J Virol; 2000 Sep; 74(18):8524-31. PubMed ID: 10954553
[TBL] [Abstract][Full Text] [Related]
20. Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors.
Yanchunas J; Langley DR; Tao L; Rose RE; Friborg J; Colonno RJ; Doyle ML
Antimicrob Agents Chemother; 2005 Sep; 49(9):3825-32. PubMed ID: 16127059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
